Abstract:Background Lung cancer has the highest cancer-related mortality worldwide. Lung adenocarcinoma (LUAD) is the most common histological subtype of non-small cell lung cancer (NSCLC). Chromatin licensing and DNA replication factor 1 (CDT1), a key regulator of cell cycle control and replication in eukaryotic cells, has been implicated in various cancer-related processes. Given its significant role in cancer, the focus on CDT1 in this study is justified as it holds promise as a potential biomarker or therapeutic target for cancer treatment. However, its prognostic value in lung adenocarcinoma (LUAD) remains unclear. Methods Bioinformatics analysis was conducted using data obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases were utilized to predict biological processes and signaling pathways, respectively. The LinkedOmics database was employed to identify differentially expressed genes (DEGs) associated with CDT1. Nomograms and Kaplan-Meier plots were generated to assess the survival rates of patients with lung adenocarcinoma (LUAD). To determine the RNA and protein expression levels of CDT1 in LUAD and adjacent normal tissues, quantitative polymerase chain reaction (qPCR) and immunohistochemistry techniques were employed, respectively. Results CDT1 was upregulated in the vast majority of cancer tissues, based on pan-cancer analysis in TCGA and GEO datasets, as to lung cancer, the level of CDT1 expression was much higher in LUAD tissue than in healthy lung tissue. Our clinical data supported these findings. In our study, we used a specific cutoff value to dichotomize the patient samples into high and low CDT1 expression groups. The Kaplan–Meier survival curve revealed poor survival rates in CDT1 high expression group than the low expression group. To determine if CDT1 expression was an independent risk factor in LUAD patients, univariate and multivariate Cox regression analyses were performed. The result showed that CDT1 was a potential novel prognosis factor for LUAD patients, whose prognosis was poorer when CDT1 expression was higher. Based on functional enrichment analysis, highly expressed DEGs of CDT1-high patients were predicted to be involved in the cell cycle. According to our analysis of immune infiltration, CDT1 exhibited a strong correlation with specific immune cell subsets and was found to be a significant predictor of poor survival in patients with LUAD. Conclusions Our research found that CDT1 was upregulated in LUAD and that high CDT1 expression predicted poor prognosis. We comprehensively and systematically analyzed the expression level in the datasets as well as in our own clinical samples, we also evaluated the prognostic and diagnostic value of CDT1, and finally, the potential mechanisms of CDT1 in the progression of LUAD. These results suggested that CDT1 may be a prognostic marker and therapeutic target for LUAD.

MCTS1 Promotes the Development of Lung Adenocarcinoma by Regulating E2F1 Expression

MTHFD2 Promotes Tumorigenesis and Metastasis in Lung Adenocarcinoma by Regulating AKT/GSK‐3β/β‐catenin Signalling

CDT1, transcriptionally regulated by E2F2, promotes lung adenocarcinoma progression

PCYT1A Suppresses Proliferation and Migration Via Inhibiting Mtorc1 Pathway in Lung Adenocarcinoma.

TCTP Promotes Epithelial-Mesenchymal Transition in Lung Adenocarcinoma.

MCTS1 Promotes Invasion and Metastasis of Oral Cancer by Modifying the EMT Process

Meiotic nuclear divisions 1 (MND1) fuels cell cycle progression by activating a KLF6/E2F1 positive feedback loop in lung adenocarcinoma

MNX1 Facilitates the Malignant Progress of Lung Adenocarcinoma Through Transcriptionally Upregulating CCDC34

Low Expression MCEMP1 Promoting Lung Adenocarcinoma Progression by and its Clinical Value

Molecular Mechanism of Cyclin E1 in Lung Adenocarcinoma and Their Cellular Response

<p>TCTP promotes epithelial&ndash;mesenchymal transition in lung adenocarcinoma</p>

MLLT3 knockdown suppresses proliferation and cell mobility in human lung adenocarcinoma

CCT6A facilitates lung adenocarcinoma progression and glycolysis via STAT1/HK2 axis

Identification of CDT1 as a prognostic marker in human lung adenocarcinoma using bioinformatics approaches

ITGB1-DT Facilitates Lung Adenocarcinoma Progression via Forming a Positive Feedback Loop With ITGB1/Wnt/β-Catenin/MYC

Methyl-CpG Binding Domain Protein 2 Inhibits the Malignant Characteristic of Lung Adenocarcinoma Through the Epigenetic Modulation of 10 to 11 Translocation 1 and Mir-200S.

LINC00491 Facilitates Tumor Progression of Lung Adenocarcinoma Via Wnt/β-Catenin-Signaling Pathway by Regulating MTSS1 Ubiquitination

Suppression of CCT3 Inhibits Tumor Progression by Impairing ATP Production and Cytoplasmic Translation in Lung Adenocarcinoma.

Cystatin SN Promotes Epithelial-Mesenchymal Transition and Serves As a Prognostic Biomarker in Lung Adenocarcinoma

MUC1-associated Proliferation Signature Predicts Outcomes in Lung Adenocarcinoma Patients

MTA1 Promotes Epithelial to Mesenchymal Transition and Metastasis in Non-Small-cell Lung Cancer